Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03889925 · ClinicalTrials.gov registry record · Phase 2
Effect of Different Injection Regimens of Autologous Conditioned Plasma for Knee Osteoarthritis
A Phase 2 study, sponsored by Andrews Research & Education Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
NCT03889925 is a Phase 2 study that has completed, run by Andrews Research & Education Foundation. The registered enrollment target is 64 participants.
The verdict
NCT03889925, a Phase 2 study, has completed, sponsored by Andrews Research & Education Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
Study Summary
The clinical efficacy of hyaluronic acid or corticosteroid injections has been reported, but effects are short lived. This has led to the development of additional injection options such as autologous derived blood products which have been documented to alleviate symptoms related to knee osteoarthritis, with recent comparative studies suggesting a greater, long-lasting effect with these blood derived products like platelet rich plasma (PRP) \[2-8\]. One clinically-developed preparation of platelet rich plasma, named autologous conditioned plasma (ACP), has randomized controlled trial data proving efficacy \[4,9\]. Clinical use of platelet rich plasma for knee arthritis typically involves a 3-injection series over 3 weeks, i.e. an injection once a week for three weeks. The main objective of this study is to determine if hyaluronic acid (HA) injected at the same time as autologous conditioned plasma (ACP), a leukocyte-poor platelet rich plasma product, will improve the performance of ACP in the treatment of symptomatic knee osteoarthritis. It is hypothesized that the injection of hyaluronic acid will improve the efficacy of ACP.
Interventions
- DRUG Hyaluronan
- BIOLOGICAL Autologous conditioned plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2019-03-15 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03889925
The ClinicalTrials.gov registry entry for NCT03889925 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrews Research & Education Foundation, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hyaluronan is the first listed.
NCT03889925 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03889925 about?
NCT03889925 is a clinical study titled "Effect of Different Injection Regimens of Autologous Conditioned Plasma for Knee Osteoarthritis". The clinical efficacy of hyaluronic acid or corticosteroid injections has been reported, but effects are short lived. This has led to the development of additional injection options such as autologous derived blood products which have been documented to alleviate symptoms related to knee osteoarthri...
What is the current status of trial NCT03889925?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2019-03-15. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT03889925?
The interventions under investigation include: Hyaluronan (DRUG), Autologous conditioned plasma (BIOLOGICAL).
Who is sponsoring clinical trial NCT03889925?
This trial is sponsored by Andrews Research & Education Foundation, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.